false
0001645469
0001645469
2023-07-11
2023-07-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 11, 2023
MONOPAR THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
| |
Delaware |
|
001-39070 |
|
32-0463781 |
|
| |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
| |
1000 Skokie Blvd., Suite 350, Wilmette, IL |
|
60091 |
|
| |
(Address of principal executive offices) |
|
(Zip Code) |
|
(847) 388-0349
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| |
Title of each class |
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
| |
Common Stock, $0.001 par value |
|
MNPR |
|
The Nasdaq Stock Market LLC
(Nasdaq Capital Market)
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|
Item 7.01
|
Regulation FD Disclosure.
|
On July 11, 2023, Monopar Therapeutics Inc. (Monopar) issued a press release announcing a collaboration with the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) to evaluate radiopharmaceutical versions of MNPR-101 in several aggressive cancers.
The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Monopar Therapeutics Inc.
|
|
|
|
|
|
|
|
Date: July 11, 2023
|
By:
|
/s/ Kim R. Tsuchimoto
|
|
|
|
Name:
|
Kim R. Tsuchimoto
|
|
|
|
Title:
|
Chief Financial Officer and Director
|
|
3